Complivit Calcium-D3 chewable tablets 500mg + 200ME, No. 30 Orange

• prevention and complex therapy of osteoporosis (menopausal, senile, steroid, idiopathic);

• prevention and treatment of calcium and / or vitamin D3 deficiency.

The drug should be taken orally, preferably with meals.

Adults in the treatment of osteoporosis are prescribed 1 tab. 2-3 times / day, for the prevention of osteoporosis - 1 tab. 2 times / day

With a deficiency of calcium and vitamin D3, adults and children over 12 years of age are prescribed 1 tab. 1-2 times / day; children from 5 to 12 years old - 1-2 tablets / day; for children from 3 to 5 years old, the dose is determined by the doctor individually.

The tablets are chewed or swallowed whole.

Active ingredients:

calcium carbonate - 1.25 g, which corresponds to the calcium content - 500 mg

colecalciferol (vit. D3) in the form of granules * - 5 ?g (200 IU)

Excipients: lactose, povidone (low molecular weight polyvinylpyrrolidone), potato starch, croscarmellose sodium (vivasol), citric acid, aspartame, magnesium stearate, orange flavor (powder).

* Granulate composition: colecalciferol, butylhydroxytoluene, sucrose, gelatin, sodium aluminosilicate, medium chain triglycerides, modified starch, water.

• hypercalcemia;

• hypercalciuria;

• calcium nephrourolithiasis;

• hypervitaminosis D;

• decalcifying tumors (myeloma, bone metastases, sarcoidosis);

• osteoporosis due to immobilization;

• phenylketonuria (contains aspartame);

• pulmonary tuberculosis (active form);

• chronic renal failure;

• children under 3 years old;

• hypersensitivity to the components of the drug.

Clinical and pharmacological group: A drug that regulates the exchange of calcium and phosphorus

Pharmaco-therapeutic group: Calcium-phosphorus metabolism regulator

pharmachologic effect

Combined drug, the action of which is due to its constituent components. It regulates the exchange of calcium and phosphates, reduces resorption and increases bone density, replenishes the lack of calcium and cholecalciferol (vitamin D3) in the body, enhances calcium absorption in the intestine and phosphate reabsorption in the kidneys, and promotes bone mineralization.

Calcium is involved in the formation of bone tissue, blood coagulation, in maintaining stable cardiac activity, in the implementation of the processes of transmission of nerve impulses.

Colecalciferol promotes the absorption of calcium in the intestine, the formation and mineralization of bone and dental tissue.

The use of calcium and colecalciferol prevents an increase in the production of parathyroid hormone, which is a stimulator of increased bone resorption.

Pharmacokinetics

Colecalciferol is absorbed from the small intestine.

Calcium is absorbed in ionized form in the proximal small intestine through an active, vitamin D-dependent transport mechanism.

Indications

• prevention and complex therapy of osteoporosis (menopausal, senile, steroid, idiopathic);

• prevention and treatment of calcium and / or vitamin D3 deficiency.

Dosage regimen

The drug should be taken orally, preferably with meals.

Adults in the treatment of osteoporosis are prescribed 1 tab. 2-3 times / day, for the prevention of osteoporosis - 1 tab. 2 times / day

With a deficiency of calcium and vitamin D3, adults and children over 12 years of age are prescribed 1 tab. 1-2 times / day; children from 5 to 12 years old - 1-2 tablets / day; for children from 3 to 5 years old, the dose is determined by the doctor individually.

The tablets are chewed or swallowed whole.

Side effect

From the digestive system: dyspeptic reactions (constipation, flatulence, nausea, stomach pain, diarrhea).

From the side of metabolism: hypercalcemia, hypercalciuria.

Others: allergic reactions.

Contraindications for use

• hypercalcemia;

• hypercalciuria;

• calcium nephrourolithiasis;

• hypervitaminosis D;

• decalcifying tumors (myeloma, bone metastases, sarcoidosis);

• osteoporosis due to immobilization;

• phenylketonuria (contains aspartame);

• pulmonary tuberculosis (active form);

• chronic renal failure;

• children under 3 years old;

• hypersensitivity to the components of the drug.

Application during pregnancy and lactation

The drug should be used with caution during pregnancy and lactation (breastfeeding).

During pregnancy, the daily dose should not exceed 1500 mg of calcium and 600 IU of vitamin D3.

Vitamin D and its metabolites can be excreted in breast milk.

Overdose during pregnancy can lead to impaired mental and physical development of the child.

Application for impaired renal function

The use of the drug is contraindicated in chronic renal failure.

Application in children

Contraindication: children under 3 years of age.

special instructions

ComplivitЃ Calcium D3 contains aspartame, which is transformed into phenylalanine in the body, therefore, the drug should not be prescribed to patients suffering from phenylketonuria.

During the period of treatment, it is necessary to constantly monitor the excretion of calcium in the urine and the concentration of calcium and creatinine in the blood plasma. In case of occurrence of calciuria exceeding 7.5 mmol / day (300 mg / day), it is necessary to reduce the dose or stop taking the drug.

In older people, the need for calcium is 1500 mg / day, for colecalciferol - 500-1000 IU / day.

To avoid overdose, it is necessary to take into account the additional intake of cholecalciferol from other sources.

Overdose

Symptoms : thirst, polyuria, decreased appetite, nausea, vomiting, constipation, dizziness, weakness, headache, fainting, coma; with prolonged use - calcification of blood vessels and tissues; laboratory parameters - hypercalciuria, hypercalcemia (calcium in plasma about 2.6 mmol).

Treatment: rehydration, 'loop' diuretics, corticosteroids, calcitonin, bisphosphonates, calcium-restricted diet, hemodialysis.

If symptoms of an overdose are detected, the patient should consult a doctor.

Drug interactions

The activity of colecalciferol may decrease when it is used simultaneously with phenytoin or barbiturates.

With simultaneous treatment with cardiac glycosides, it is necessary to monitor the ECG and the clinical condition, because calcium preparations can potentiate the therapeutic and toxic effects of cardiac glycosides.

Calcium and colecalciferol preparations can increase the absorption of tetracyclines from the gastrointestinal tract. Therefore, the time interval between taking drugs should be at least 3 hours.

To prevent a decrease in the absorption of bisphosphonates or sodium fluoride preparations, it is recommended to take ComplivitЃ Calcium D3 no earlier than two hours after taking them.

GCS reduce absorption, therefore, when treating GCS, an increase in the dose of ComplivitЃ Calcium D3 may be required.

Simultaneous treatment with cholestyramine preparations or laxatives based on mineral or vegetable oil may reduce the absorption of cholecalciferol.

With the simultaneous use of thiazide diuretics, the risk of developing hypercalcemia increases, because they increase tubular calcium reabsorption. Furosemide and other loop diuretics, on the other hand, increase the excretion of calcium by the kidneys.

Storage conditions

The drug should be stored out of the reach of children, in a dry, dark place at a temperature not exceeding 25 ? C.

Shelf life

Shelf life is 2 years.

Terms of sale

The drug is approved for use as a means of OTC.

Contacts for inquiries

PHARMSTANDART JSC (Russia)